Inozyme Pharma Inc - Asset Resilience Ratio
Inozyme Pharma Inc (INZY) has an Asset Resilience Ratio of 61.92% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Inozyme Pharma Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Inozyme Pharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Inozyme Pharma Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Inozyme Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore INZY long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.93 Million | 61.92% |
| Total Liquid Assets | $58.93 Million | 61.92% |
Asset Resilience Insights
- Very High Liquidity: Inozyme Pharma Inc maintains exceptional liquid asset reserves at 61.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Inozyme Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Inozyme Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Inozyme Pharma Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Inozyme Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 74.69% | $92.01 Million | $123.18 Million | -1.98pp |
| 2023-12-31 | 76.68% | $154.00 Million | $200.85 Million | +8.46pp |
| 2022-12-31 | 68.21% | $94.95 Million | $139.19 Million | -3.41pp |
| 2021-12-31 | 71.62% | $88.48 Million | $123.54 Million | +0.97pp |
| 2020-12-31 | 70.65% | $119.66 Million | $169.36 Million | +38.27pp |
| 2019-12-31 | 32.39% | $15.53 Million | $47.94 Million | +15.86pp |
| 2018-12-31 | 16.53% | $7.20 Million | $43.54 Million | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more